Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute

• US 4,716,154 A
• Filed: 12/03/1985
• Issued: 12/29/1987
• Est. Priority Date: 06/08/1984
• Status: Expired due to Term

• Current Assignee: Pharmacia AB (Pharmacia Corp.)
• Original Assignee: Pharmacia AB (Pharmacia Corp.)
• Inventors: Malson, Tomas, Lindqvist, Bengt L.
• Primary Examiner(s): Brown, J. R.
• Assistant Examiner(s): Peselev, Elli
• Application Number:
  US06/844,388
• Time in Patent Office: 756 Days
• Field of Search: 514/54, 536/41
• US Class Current: 514/54
• CPC Class Codes: A61F 2/14 Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

The invention is concerned with a vitreous humor substitute intended for ophthalmological uses and consisting of a gel of crosslinked hyaluronic acid and a method at retinal surgery and after vitrectomy when the vitreous humor completely or partially is exchanged for such a gel.

Claims

1. In the retinal surgery method in which a viscous fluid is introduced into an intraocular space enclosed between a rear boundary formed by the retina and a frontal boundry normally formed by the lens and the ciliary body, so that the pressure applied on the receptor layer by the viscous fluid, conjointly with any remaining portions of natural humor, will cause the receptor layer to lie in contact with the pigment epithelial layer for a period of time sufficient for healing, the improvement comprising that said viscous fluid contains a sterile and pyrogen-free gel of cross-linked hyaluronic acid.

3. A method according to claim 1 in which the gel has a dry solids content of from 0.1 to 50% by weight.

5. A method according to claim 1 in which the gel has a dry solids content of from 0.2 to 25% by weight.

7. A method according to claim 1 in which cross-linking of hyaluronic acid has been effected with at least one reagent forming ether or amide bridges to the hyaluronic acid molecules.

8. A method according to claim 7 in which said reagent is a bifunctional or polyfunctional epoxide, or a corresponding halohydrin or epihalohydrin or halide.

12. A method according to claim 3 in which cross-linking of hyaluronic acid has been effected with at least one reagent forming ether or amide bridges to the hyaluronic acid molecules.

13. A method according to claim 12 in which said reagent is a bifunctional or polyfunctional epoxide, or a corresponding halohydrin or epihalohydrin or halide.

14. A method according to claim 3 wherein the cross-linking reaction has been carried out with an amount of cross-linking agent equal to a molar ratio of 0.03 to 4.0 per disaccharide repeating unit of the hyaluronic acid molecule.

2. In the method following vitrectomy in which a viscous fluid is introduced into an intraocular space enclosed between a rear boundary formed by the retina and a frontal boundary normally formed by the lens and the ciliary body or in aphatic eyes formed by the cornea, in a manner such that said viscous fluid, together with any remaining natural vitreous humor, will fill out all of said intraocular space, the improvement comprising that said viscous fluid contains a sterile and pyrogen-free gel of crosslinked hyaluronic acid.

4. A method according to claim 2 in which the gel has a dry solids content of from 0.1 to 50% by weight.

6. A method according to claim 2 in which the gel has a dry solids content of from 0.2 to 25% by weight.

9. A method according to claim 2 in which cross-linking of hyaluronic acid has been effected with at least one reagent forming ether or amide bridges to the hyaluronic acid molecules.

10. A method according to claim 9 in which said reagent is a bifunctional or polyfunctional epoxide, or a corresponding halohydrin or epihalohydrin or halide.

11. A method according to claim 2 wherein the cross-linking reaction has been carried out with an amount of cross-linking agent equal to a molar ratio of 0.03 to 4.0 per disaccharide repeating unit of the hyaluronic acid molecule.

15. A method according to claim 4 in which cross-linking of hyaluronic acid has been effected with at least one reagent forming ether or amide bridges to the hyaluronic acid molecules.

16. A method according to claim 15 in which said reagent is a bifunctional or polyfunctional epoxide, or a corresponding halohydrin or epihalohydrin or halide.